Page last updated: 2024-11-07

penicillamine and Alzheimer Disease

penicillamine has been researched along with Alzheimer Disease in 11 studies

Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research Excerpts

ExcerptRelevanceReference
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event."8.12Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event."4.12Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. ( Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)
"Some of the implications are that Alzheimer's disease and other diseases of neurodegeneration and fibrotic, inflammatory, and autoimmune diseases may be treatable by lowering the availability of free copper."2.44The risks of free copper in the body and the development of useful anticopper drugs. ( Brewer, GJ, 2008)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's7 (63.64)29.6817
2010's1 (9.09)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Moret, V1
Laras, Y1
Pietrancosta, N1
Garino, C1
Quéléver, G1
Rolland, A1
Mallet, B1
Norreel, JC1
Kraus, JL1
Bu, K1
Patel, D1
Morris, R1
Han, W1
Umeukeje, G1
Zhu, T1
Cheng, F1
Cilliers, K1
Sun, D1
Zhang, W1
Yu, Q1
Chen, X1
Xu, M1
Zhou, Y1
Liu, J1
Brewer, GJ1
Rossi, L2
Squitti, R2
Pasqualetti, P2
Marchese, E1
Cassetta, E2
Forastiere, E1
Rotilio, G1
Rossini, PM2
Finazzi-Agró, A2
Cui, Z1
Lockman, PR1
Atwood, CS1
Hsu, CH1
Gupte, A1
Allen, DD1
Mumper, RJ1
Gasparini, L1
Ghidoni, R1
Alberici, AC1
Benussi, L1
Moratto, D1
Trabucchi, M1
Growdon, JH1
Nitsch, RM1
Binetti, G1
Fass, U1
Panickar, K1
Personett, D1
Bryan, D1
Williams, K1
Gonzales, J1
Sugaya, K1
McKinney, M1
Cherny, RA1
Barnham, KJ1
Lynch, T1
Volitakis, I1
Li, QX1
McLean, CA1
Multhaup, G1
Beyreuther, K1
Tanzi, RE1
Masters, CL1
Bush, AI1
Moffa, F1
Cortesi, M1
Colloca, A1

Reviews

2 reviews available for penicillamine and Alzheimer Disease

ArticleYear
Trace element alterations in Alzheimer's disease: A review.
    Clinical anatomy (New York, N.Y.), 2021, Volume: 34, Issue:5

    Topics: Alzheimer Disease; Clioquinol; Copper; Deferoxamine; Humans; Metals; Penicillamine; Siderophores; Tr

2021
The risks of free copper in the body and the development of useful anticopper drugs.
    Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:6

    Topics: Alzheimer Disease; Angiogenesis Inhibitors; Autoimmunity; Copper; Fibrosis; Hepatolenticular Degener

2008

Trials

2 trials available for penicillamine and Alzheimer Disease

ArticleYear
Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine.
    Neuroscience letters, 2002, Aug-30, Volume: 329, Issue:2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Copper; D

2002
d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.
    European journal of clinical investigation, 2002, Volume: 32, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chelating Agents; Copper; Disease Progression; Female; H

2002

Other Studies

7 other studies available for penicillamine and Alzheimer Disease

ArticleYear
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
    Bioorganic & medicinal chemistry letters, 2006, Jun-15, Volume: 16, Issue:12

    Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Copper; Heterocyclic Compounds, 1-Ring; Mo

2006
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
    Journal of Alzheimer's disease : JAD, 2022, Volume: 89, Issue:2

    Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine

2022
Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer's disease.
    Journal of colloid and interface science, 2017, Nov-01, Volume: 505

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Survival; Me

2017
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2005, Volume: 59, Issue:2

    Topics: Alzheimer Disease; Central Nervous System Diseases; Chelating Agents; Copper; Drug Carriers; Drug St

2005
Modulation of presenilin-1 processing by nitric oxide during apoptosis induced by serum withdrawal and glucose deprivation.
    Annals of the New York Academy of Sciences, 1999, Volume: 893

    Topics: Alzheimer Disease; Apoptosis; Benzoates; Culture Media, Serum-Free; Cytochrome c Group; Deoxyglucose

1999
Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess.
    Neuroreport, 2000, Apr-07, Volume: 11, Issue:5

    Topics: Acetylcholine; Alzheimer Disease; Animals; Brain Stem; Cell Survival; Cells, Cultured; Choline O-Ace

2000
Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
    Journal of structural biology, 2000, Volume: 130, Issue:2-3

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chelating Agents; Copper; Humans; Mice; Mi

2000